Glenmark Pharmaceuticals (GLENMARK) Share Price Rises 2.14% to Rs 2,317.45 Today
- September 29, 2026
- Posted by: Kunal Singla
- Category: News
The Glenmark Pharmaceuticals Share Price rose 2.14% on 28 October 2026, with the stock last traded at Rs 2,317.45 as of 2:37 PM IST against a previous close of Rs 2,268.90. The gain works out to Rs 48.55 per share, and Glenmark Pharmaceuticals Ltd. carries a market capitalisation of Rs 62,907.88 crore.
The price move is confirmed in Univest data; a company-specific reason has not been established. This Glenmark Pharmaceuticals Stock News update therefore sticks to what the numbers show: the price move, the valuation and return ratios, the Healthcare sector benchmark and how the stock compares with listed pharmaceutical peers.
Glenmark Pharmaceuticals Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,317.45 |
| Previous Close | Rs 2,268.9 |
| Today's Move | Rs 48.55 (+2.14%) |
| Open | Rs 2,259.65 |
| High | Rs 2,318.3 |
| Low | Rs 2,259.65 |
| Market Capitalisation | Rs 62,907.88 crore |
| Market Cap Category | Large Cap |
Glenmark Pharmaceuticals Ltd. (GLENMARK) rose to Rs 2,317.45 from the previous close of Rs 2,268.9, a move of Rs 48.55 or 2.14%. The stock opened at Rs 2,259.65, reached a high of Rs 2,318.3, recorded a low of Rs 2,259.65.
The Glenmark Pharmaceuticals Share Price Today stands at Rs 2,317.45, which is Rs 48.55 or 2.14% above the previous close of Rs 2,268.90. The move is a same-day price rise, and the stock is trading very close to the top of its range for the day.
The stock opened at Rs 2,259.65, below the previous close, and that level is also the day low. It has since moved up to a high of Rs 2,318.30. At Rs 2,317.45, the Glenmark Pharmaceuticals Share Price is Rs 57.80 above both its opening level and the day low, and just Rs 0.85 below the day high. Because the day low sat below the previous close, the stock has recovered from that level and moved above it through today’s trade.
Market capitalisation of Rs 62,907.88 crore frames the size of the company behind this Glenmark Pharmaceuticals Share Price Rise. Market capitalisation describes size, not quality, so the valuation and return ratios are the next place to look.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 62,907.88 crore |
| P/E Ratio | 35.62x |
| P/B Ratio | 5.84x |
| ROE | 14.1% |
| ROCE | 20.35% |
| EPS | Rs 63.7 |
| Book Value Per Share | Rs 388.43 |
| Dividend Yield | 0.11% |
Glenmark Pharmaceuticals Ltd. (GLENMARK) fundamental metrics show P/E 35.62x, P/B 5.84x, ROE 14.1%, ROCE 20.35%. These ratios show where the company stands today and are not a call to buy or sell.
Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 62,907.88 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 35.62x, P/B at 5.84x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 14.1% and ROCE of 20.35%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 63.7, book value per share of Rs 388.43, dividend yield of 0.11%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.74x, median ROE of 11.23%, median ROCE of 13.17%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 35.62x |
| Benchmark Median P/E | 30.74x |
| Benchmark Average P/E | 43.3x |
| Benchmark P/E Range | 3.21x to 577.05x |
| Company P/B Ratio | 5.84x |
| Benchmark Median P/B | 2.71x |
| Company ROE | 14.1% |
| Benchmark Median ROE | 11.23% |
| Company ROCE | 20.35% |
| Benchmark Median ROCE | 13.17% |
| Company Market Capitalisation | Rs 62,907.88 crore |
| Benchmark Median Market Cap | Rs 696.43 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 35.62x, which is above the benchmark median of 30.74x, a difference of +15.88%. A P/E difference of this kind is a reference point rather than a recommendation.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROE of 14.1%, which is above the benchmark median of 11.23%, a difference of +25.56%. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROCE of 20.35%, which is above the benchmark median of 13.17%, a difference of +54.52%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,18,204.09 | 34.91 | 4.88 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,40,780 | 86.02 | 14.25 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,73,828.11 | 82.48 | 9.53 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,520.92 | 25.79 | 4.32 | 19.69 | 21.39 |
| Laurus Labs Ltd. | LAURUSLABS | 1,11,304.32 | 105.74 | 20.5 | 18.31 | 18.2 |
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 35.62x compared with the displayed peer median of 82.48x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 14.1% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 20.35% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 62,907.88 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Glenmark Pharmaceuticals
Several verified data points shape how the market is reading Glenmark Pharmaceuticals today:
- The stock rose 2.14% to Rs 2,317.45, a gain of Rs 48.55 over the previous close of Rs 2,268.90.
- It traded between Rs 2,259.65 and Rs 2,318.30, and currently sits Rs 0.85 below the day high.
- ROE of 14.10% and ROCE of 20.35% are above the industry benchmark medians of 11.23% and 13.17%.
- The P/E of 35.62 and P/B of 5.84 sit above the benchmark medians of 30.74 and 2.71.
- EPS is Rs 63.70, book value is Rs 388.43 per share and the dividend yield stands at 0.11%.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a listed company in the Healthcare sector, operating in the Pharmaceuticals & Drugs industry. It trades under the symbol GLENMARK and has a market capitalisation of Rs 62,907.88 crore. Within its 199-company industry benchmark, it sits far above the median by market capitalisation and posts return ratios above the benchmark median.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is the Glenmark Pharmaceuticals Share Price rising today?
Ans. The Glenmark Pharmaceuticals Share Price rose 2.14% to Rs 2,317.45 from a previous close of Rs 2,268.90. According to Univest data, the price event is confirmed, but no company-specific catalyst is established today.
What is the Glenmark Pharmaceuticals Share Price today?
Ans. The Glenmark Pharmaceuticals Share Price last traded at Rs 2,317.45 as of 2:37 PM IST on 28 October 2026, up Rs 48.55 from the previous close of Rs 2,268.90, with a day range of Rs 2,259.65 to Rs 2,318.30.
What is the market capitalisation of Glenmark Pharmaceuticals?
Ans. Glenmark Pharmaceuticals has a market capitalisation of Rs 62,907.88 crore. Market capitalisation reflects size rather than quality, and it sits far above the Pharmaceuticals & Drugs benchmark median of Rs 696.43 crore across 199 companies.
What is the P/E ratio of Glenmark Pharmaceuticals?
Ans. The P/E ratio of Glenmark Pharmaceuticals is 35.62, which sits above the same-industry benchmark median of 30.74 and below the average of 43.3. The P/B ratio is 5.84 against a benchmark median of 2.71.
What are the ROE and ROCE of Glenmark Pharmaceuticals?
Ans. Glenmark Pharmaceuticals reports ROE of 14.10% and ROCE of 20.35%. Both sit above the industry benchmark medians of 11.23% for ROE and 13.17% for ROCE, based on the same-industry peer group of 199 companies.
What is the EPS and book value of Glenmark Pharmaceuticals?
Ans. EPS of Glenmark Pharmaceuticals is Rs 63.70, and book value per share is Rs 388.43. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share.
What is the dividend yield of Glenmark Pharmaceuticals?
Ans. The dividend yield of Glenmark Pharmaceuticals is 0.11%. This is a historical and current figure relative to the present Glenmark Pharmaceuticals Share Price, and it does not guarantee any dividend in the future.
How does Glenmark Pharmaceuticals compare with Sun Pharma and Zydus Lifesciences?
Ans. Glenmark Pharmaceuticals has a P/E of 35.62 against 34.91 for Sun Pharma and 25.79 for Zydus Lifesciences. Its ROE of 14.10% is below Sun Pharma at 14.85% and Zydus Lifesciences at 19.69%.
Track Glenmark Pharmaceuticals Share Price on Univest
Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Readers who want to follow the Glenmark Pharmaceuticals Share Price through the day can track the live share price, fundamental ratios, 52-week levels and market insights for Glenmark Pharmaceuticals on Univest. The stock page brings valuation multiples, return ratios and sector comparisons together, so users can check how the Glenmark Pharmaceuticals Share Price moves against its fundamentals. This article is for information only and is not a recommendation.
